RT Journal Article SR Electronic T1 A rare missense variant in the ATP2C2 gene is associated with language impairment and related measures JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.01.12.21249315 DO 10.1101/2021.01.12.21249315 A1 Angela Martinelli A1 Mabel Rice A1 Joel B. Talcott A1 Rebeca Diaz A1 Shelley Smith A1 Muhammad Hashim Raza A1 Margaret J. Snowling A1 Charles Hulme A1 John Stein A1 Marianna E. Hayiou-Thomas A1 Ziarih Hawi A1 Lindsey Kent A1 Samantha J. Pitt A1 Dianne F. Newbury A1 Silvia Paracchini YR 2021 UL http://medrxiv.org/content/early/2021/01/15/2021.01.12.21249315.abstract AB At least 5% of children present unexpected difficulties in expressing and understanding spoken language. This condition is highly heritable and often co-occurs with other neurodevelopmental disorders such as dyslexia and ADHD. Through an exome sequencing analysis, we identified a rare missense variant (chr16:84405221, GRCh38.p12) in the ATP2C2 gene. ATP2C2 was implicated in language disorders by linkage and association studies, and exactly the same variant was reported previously in a different exome sequencing study for language impairment (LI). We followed up this finding by genotyping the mutation in cohorts selected for LI and comorbid disorders. We found that the variant had a higher frequency in LI cases (1.8%, N=360) compared to cohorts selected for dyslexia (0.8%, N = 520) and ADHD (0.7%, N = 150), which presented frequencies comparable to reference databases (0.9%, N = 24,046 gnomAD controls). Additionally, we observed that carriers of the rare variant identified from a general population cohort (N=42, ALSPAC cohort) presented, as a group, lower scores on a range of reading and language-related measures compared to controls (N=1825) (minimum p = 0.002 for nonword reading). ATP2C2 encodes for an ATPase (SPCA2) that transports calcium and manganese ions into the Golgi lumen. Our functional characterization suggested that the rare variant influences the ATPase activity of SPCA2. Thus, our results further support the role of ATP2C2 locus in language-related phenotypes and pinpoint the possible effects of a specific rare variant at molecular level.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSP if funded by the Royal Society. This work was supported by an Action Medical Research Action/The Chief Scientist (CSO) Office, Scotland grant (GN2614) and a Cunningham Trust grant to SP and SJP. Support to the analysis was provided by the St Andrews Bioinformatics Unit funded by the Wellcome Trust [grant 105621/Z/14/Z]. Assessment of the Aston cohort was supported by funding from The Waterloo Foundation to JBT and SP [797/1720]. Analysis of the discovery pedigree was supported by the University of Kansas grant (NIH:NIDCD 5 R01 DC001803). Analysis of the York cohort was funded by Wellcome Trust Programme Grant 082036/B/07/Z. DFN is currently supported by Oxford Brookes University funds, the Leverhulme Trust and the British Academy. This work was, in part, completed while DFN was at the Wellcome Trust Centre for Human Genetics, Oxford as an MRC Career Development Fellow (G1000569/1). The UK Medical Research Council and Wellcome (Grant ref: 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. This publication is the work of the authors and DFN will serve as guarantors for the analysis of the ALSPAC data presented in this paper. A comprehensive list of grants funding is available on the ALSPAC website (http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf). Whole genome sequencing of the ALSPAC samples was performed as part of the UK10K onsortium (a full list of investigators who contributed to the generation of the data is available from www.UK10K.org.uk). ALSPAC GWAS data was generated by Sample Logistics and Genotyping Facilities at Wellcome Sanger Institute and LabCorp (Laboratory Corporation of America) using support from 23andMe.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Local ethics committees of Universities and Hospitals - Review boards at the University of Kansas and at the University of Nebraska Medical Center; Yorkshire & The Humber - Humber Bridge NHS Research Ethics; Ethics Committee at the University of York - Department of Psychology; Oxfordshire Psychiatric Research Ethics Committee; Aston University Ethics Committee; Trinity College Dublin in Ireland; University of Birmingham in UK; ALSPAC Law and Ethics CommitteeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used in this study are available from UK10K Data Access Committee and the ALSPAC Executive Committee for researchers who meet the criteria for access to confidential data.